Autolus Therapeutics Delays Q1 Earnings Release

Autolus Therapeutics plc has announced a delay in the release of its first quarter 2024 earnings and the corresponding conference call. The company intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission later in the week, allowing for an automatic extension of five additional calendar days to file the Q1 2024 10-Q, which is due on May 15, 2024.

In light of this delay, the previously scheduled earnings release and call, set to take place before U.S. market open on May 14, 2024, have been canceled. The company aims to file the Q1 2024 10-Q as soon as practicable and no later than the May 20, 2024 deadline in compliance with Rule 12b-25.

As a result of the delay, the company has rescheduled its first quarter 2024 conference call and webcast to May 17, 2024, at 8:30 am EDT/1:30 pm BST. This event will provide an opportunity to discuss the company’s financial results and offer a general business update. Conference call participants are required to pre-register to receive the dial-in numbers and a personal PIN, which are necessary to access the conference call. A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

For further details, the company has provided contact information for Olivia Manser, Julia Wilson, and Susan A. Noonan.

As the situation develops, investors and stakeholders will be keen to see how this delay may impact the company's financial performance and strategic direction. Today the company's shares have moved 0.1% to a price of $4.0. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.